In comparison to three prominent BET inhibitors currently in clinical development, namely BMS-986158, OTX015, and GSK525762, NHWD-870 exhibits greater potency, as evidenced by a cytometric assay.94 Currently, NHWD-870 is undergoing Phase I clinical trials for the treatment of various kinds of cancer (CXHL200250). This evidence concerns the gene DNER and cancer.